Authors

Latest:

Dr. Thomas Discusses the Potential Utility for PF-03446962 in HCC

Melanie B. Thomas, MD, medical oncologist, associate director for clinical trials, Hollings Cancer Center, Medical University of South Carolina, discusses the potential utility for the monoclonal antibody PF-03446962 in hepatocellular carcinoma (HCC).

Melanie C. Majure, MD

Latest:

Dr. Majure on Unmet Needs for Patients With TNBC

Melanie C. Majure, MD, assistant clinical professor in the Division of Hematology/Oncology and breast oncologist, University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, discusses unmet needs for patients with triple-negative breast cancer (TNBC).

Melanie E. Royce, MD, PhD

Latest:

Dr. Royce on Progress Being Made in HER2+ Positive Breast Cancer

Melanie E. Royce, MD, PhD, co-director, Protocol Review and Monitoring System, member, Women’s Cancers Research Program, associate professor of Medicine, University of New Mexico Comprehensive Cancer Center, discusses some of the progress currently being made in the field of HER2-positive breast cancer.

Meletios A. Dimopoulos, MD

Latest:

Dr Dimopoulos on Efficacy Findings From the DREAMM-8 Trial in Multiple Myeloma

Meletios Dimopoulos, MD, discusses the design of and findings from the DREAMM-8 trial investigating BPd in patients with multiple myeloma.

Meletios A. Dimopoulos, MD, The National and Kapodistrian University of Athens

Latest:

“Multiple Myeloma Talk”: A Review of Data from the ASH 2020 Virtual Meeting

Meletios Dimopoulos, MD

Latest:

Dr. Dimopoulos Reflects on Ibrutinib Plus Rituximab in Waldenstrom Macroglobulinemia

Meletios Dimopoulos, MD, professor and chairman, Department of Clinical Therapeutics at the University of Athens School of Medicine, Athens, Greece, discusses the impact of the results from the iNNOVATE study of ibrutinib (Imbruvica) plus rituximab (Rituxan) in patients with Waldenström macroglobulinemia.

Melinda L. Irwin, PhD

Latest:

Melinda Irwin on Impact of Exercise on Survivors' Quality of Life

Melinda Liggett Irwin, PhD, MPH, associate professor of epidemiology (chronic diseases), Yale School of Public Health, co-program leader, Cancer Prevention and Control Research Program, Yale Cancer Center, discusses the impact of the LIVESTRONG at the YMCA Program on survivors' fitness, physical activity, and quality of life.

Melissa A. Wilson, MD, PhD

Latest:

Dr. Wilson on Choosing Between BRAF/MEK Therapies for Patients With Melanoma

Melissa A. Wilson, MD, PhD, an assistant professor of medicine at Perlmutter Cancer Center at NYU Langone Medical Center, discusses how physicians select between the 2 BRAF/MEK inhibitor combination regimens for their patients with melanoma.

Melissa Andres, BSN, RN, OCN, CBPN-C

Latest:

The Heart of Collaboration: Oncologists and Nurses Working Together

The culture of the nurse-physician relationship has changed dramatically over the past years and is one of the most important drivers of a healthy work environment

Melissa Burgess, MD

Latest:

Dr. Burgess on Pembrolizumab in Sarcoma

In the phase II SARC028 trial, single-agent pembrolizumab (Keytruda) demonstrated antitumor activity in patients with advanced soft tissue and bone sarcomas.

Melissa Hardesty, MD

Latest:

Dr. Hardesty on Bevacizumab/PARP Inhibitor Combination in Ovarian Cancer

Melissa Hardesty, MD, gynecologic oncologist, Alaska Women’s Cancer Center, discusses the safety and efficacy of the bevacizumab/PARP inhibitor combination in ovarian cancer.

Melissa Johnson, MD

Latest:

Treatment Strategies for NSCLC With Concomitant KRAS and p53 Mutations

Before closing out their discussion on IO therapy in non–small cell lung cancer, Melissa Johnson, MD, and Joshua Sabari, MD, identify treatment strategies in the setting of concomitant KRAS/p53 mutation.

Melissa K. Accordino, MD, MS

Latest:

Dr. Accordino on Utility of Liquid Biopsies in Breast Cancer

Melissa K. Accordino, MD, MS, discusses the utility of liquid biopsies in breast cancer.

Melissa L. Bondy, PhD, MS

Latest:

Future Treatment Approaches for Patients With Glioma

Melissa L. Bondy, PhD, MS, Duncan Cancer Center-Bondy Cancer Prevention and Population Sciences, Baylor College of Medicine, discusses future treatment approaches for patients with glioma.

Melissa L. Johnson, MD

Latest:

Insights from ARTEMIS-001

Panelists discuss how preliminary results from the pPhase 3 ARTEMIS-001 study indicate that iIfinatamab dDeruxtecan, a B7-H3 antibody-drug conjugate, demonstrates promising antitumor activity in relapsed small cell lung cancer, with a notable partial response rate and manageable safety profile among treated patients.

Melissa P. Mitchell, MD, PhD

Latest:

New Frontier for Genomics: Radiotherapy in Early Breast Cancer

By individualizing risk of locoregional recurrence and radiosensitivity with molecular subtyping/genomic classifiers, it is hoped that use and/or extent of adjuvant radiation therapy could be tailored in early-stage breast cancer.

Melody A. Cobleigh, MD

Latest:

Dr. Cobleigh on the Focus of Future Research in HER2+ Breast Cancer

Melody A. Cobleigh, MD, a professor of medical oncology at Rush University Medical Center, discusses the focus of future research in HER2-positive breast cancer.

Melody Watson

Latest:

Positive Results from First Randomized Study Assessing T-VEC/Ipilimumab Combo in Advanced Melanoma

The addition of T-VEC (T-VEC; Imlygic), a herpes simplex virus 1-based oncolytic virus, to CTLA-4 inhibitor ipilimumab (Yervoy) improves the objective response rate in patients with unresected stage IIIb to IV melanoma.

Melvin J. Silverstein, MD, FACS

Latest:

Dr. Silverstein on Oncoplasty Versus Mastectomy for Patients With Breast Cancer

Melvin J. Silverstein, MD, FACS, medical director, Hoag Breast Center, Gross Family Foundation Endowed Chair in Oncoplastic Breast Surgery, Hoag Memorial Hospital Presbyterian, compares oncoplastic surgery with mastectomy for patients with breast cancer.

Merav Bar, MD

Latest:

Researchers Aim to Improve Blood Cancer Outcomes With Engineered T-Cell Treatments

Researchers at the Seattle Cancer Care Alliance (SCCA) have optimized special methods for modifying T cells to target specific cancer cells in patients with blood cancers.